Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program – BioSpace
Eterna Therapeutics, Inc. (Nasdaq: ERNA), a company known for its leadership in cell therapies, recently made an exciting announcement. The company’s Board of Directors has given the green light for a stock repurchase program of up to $1 million of the company’s common stock. This program is a reflection of the Board’s confidence in the company’s long-term strategy and its dedication to increasing shareholder value.
The stock repurchase program will allow the company to buy back its own shares through various methods like open market transactions or privately negotiated transactions. The company’s management will decide the timing and amount of repurchases based on market conditions, stock price, and other relevant factors. Importantly, this program doesn’t have an expiration date and could be changed or stopped at any time without prior notice.
Sanjeev Luther, the President and CEO of Eterna Therapeutics, expressed his confidence in the company’s direction, stating, “This buyback program underscores our belief in Eterna Therapeutics’ trajectory.” Eterna Therapeutics Inc. is a publicly traded company that focuses on using cutting-edge tools to develop innovative and safe off-the-shelf cell therapies for advanced solid tumors. Their lead product, ERNA-101, is currently in development and is designed to deliver specific cytokines to the tumor microenvironment to stimulate anti-tumor immunity.
For those interested in learning more about Eterna Therapeutics and their innovative work, visit their website at https://www.eternatx.com/.
This press release contains forward-looking statements within the meaning of securities laws, which aim to provide a safe harbor for future predictions. It’s important to note that forward-looking statements involve risks and uncertainties that could cause actual results to differ from what is predicted in this press release.
